PLSE May 2024 7.500 call
| Previous Close | 0.8000 |
| Open | 0.3400 |
| Bid | 0.0000 |
| Ask | 0.9000 |
| Strike | 7.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.3200 - 0.3400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 227 |
Business WirePulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
HAYWARD, Calif., May 20, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has determined a new record date for the Company’s previously announced rights offering (the "Rights Offering"), which will be available to all holders of record of the Company’s common stock, par value $0.001 per share (the "Common Stock
Business WirePulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
HAYWARD, Calif., May 16, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.
Business WirePulse Biosciences Enhances Executive Leadership Team
HAYWARD, Calif., May 14, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology ("Pulse"), today announced enhancements to its executive leadership team to support its next pivotal phase of growth.
